Close menu




May 19th, 2021 | 08:39 CEST

CureVac, The Place Holdings, TUI - New start with great potential!

  • Investments
Photo credits: pixabay.com

Finally! Due to the positive development of the vaccination program and the successful testing strategy, the incidence figures in Germany are gradually decreasing. Industries that suffered heavily from the pandemic, such as tourism and air travel, are breathing a sigh of relief. While Germans are still planning more domestic vacations during the Whitsun vacations, bookings abroad for the summer are rising disproportionately. Other countries are also increasingly focusing on domestic tourism, with considerable potential for the respective operators.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , SG1Q02920318 , DE000TUAG000

Table of contents:


    China far ahead

    While in Europe, the third wave has just been flattened out and slow steps are being taken to return to certain normality, in China, everyday life has long since returned. There is a travel boom in the Middle Kingdom, primarily within the country. According to China's Ministry of Culture and Tourism, 102 million citizens took domestic trips during the annual National Day holiday in April 2021, a figure equivalent to 94.5% of the number of trips taken during the holiday in 2019, the year before COVID-19. Tourism has become a significant contributor to China's domestic economy and is a cornerstone of the government's long-term goal of creating a consumption-driven economy.

    The emergence of an affluent middle class supports this plan. Due to the increasing economic power of consumers and the extreme inclination of the Chinese towards gaming, advertising, consumption and entertainment, the entertainment market is flourishing and new concepts are being developed. In contrast, much of China is still in a nascent phase in project and city development. Here, The Place Holdings, which is traded on the SGX in Singapore and Frankfurt, has created a perfect symbiosis of its three business segments to meet the needs of the emerging population.

    Three models in one

    The Place Holdings focuses on integrating traditional stores with omnichannel strategies and digital solutions such as "new-retail" solutions, last-mile logistics, immersive virtual reality technology, and smart connectivity for businesses to take advantage of new growth opportunities in the digital economy. The Group has built a business platform to integrate new value propositions within its 3 core businesses: real estate development and management, cultural tourism, and media-related businesses.

    To date, the debt-free Company, which has around EUR 46 million in cash, has three acquisitions in its portfolio. In the case of the Reality Centre, which was acquired in 2020 for EUR 93 million, the experienced management speculates on the claim to bonus property ratios of between 25% to 30% if a change of use occurs under the Central Business District (CBD) Incentive Scheme. The Place Holdings hold a 20% stake in MCC Land's mixed development project adjacent to the Tanah Merah MRT interchange.

    The third project, a plot of land that has only been held by a subsidiary since November, saw news of a significant revaluation last week. The size of the land is approximately 270,500.64 square meters. It is strategically located within Mount Yuntai Tourist Township, where hospitality properties, wellness resorts, integrated retail and commercial developments, and theme parks are planned and some are currently under development.

    Compared to the property's valuation of EUR 14.27 million as of September 30, 2020, the property was valued at EUR 61.29 million, up 329%, after the zoning change by one of China's leading valuation firms, which will add EUR 47.02 million to the balance sheet. Currently, the market capitalization of the Company is EUR 370.48 million. Suppose you are interested in the real estate market 2.0. in Singapore, you cannot avoid The Place Holdings. However, one should strictly limit due to the low tradability in Germany.

    When will the approval come?

    Due to the possible patent release, Panic selling gave investors a second chance with the Tübingen-based vaccine manufacturer CureVac. The share price fell from a high of EUR 110 to a low of below EUR 75. After forming a double bottom, however, the price recovered and closed the torn downward gap at around EUR 90. Yesterday, the share tested resistance at EUR 95. Breaking through the EUR 100 mark, at which the value has already failed three times on a sustained basis, is likely to be a more challenging task. Driven by the news, this could happen in June. Currently, CureVac is still in clinical trials; an application for approval should follow soon. The Tübingen-based Company is also well on schedule with its research into a second-generation vaccine that is supposed to be particularly effective against mutations. Clinical trials are expected to begin in the third quarter. If the first vaccine is approved in June, we expect a test of the old highs at EUR 125.40, at least in the short term.

    Hope dies last

    From summer, everything should get better. After further lockdowns and postponements, the travel group TUI hopes for a quick recovery of travel in the summer months. Slowly, it is also high time if one does not want to once again pump the already plundered state coffers.
    In the first two fiscal quarters of 2020/2021, from October to March, the world's largest travel provider accumulated a loss typical for the time of year. Still, at just under EUR 1.48 billion, this was more than 70% higher than in the same period last year. Currently, TUI has cash and cash equivalents of EUR 1.7 billion, with a cash outflow of EUR 300 million per month at last count. The state pumped a total of EUR 4.3 billion into the Hanover-based Group to prevent insolvency. Market capitalization is currently EUR 2.87 billion. Even though the travel business is picking up again, TUI faces major challenges in the future. Due to the uncertainties, we do not recommend an investment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by André Will-Laudien on September 26th, 2023 | 07:45 CEST

    Artificial Intelligence in Sellout! Nvidia, Defense Metals, ARM Holdings - Nothing works without rare earths!

    • Mining
    • RareEarths
    • AI
    • chips
    • Investments

    After long bull market movements, the stock market usually tends to rotate sectors, or the market enters a general consolidation. In the former case, investors can profit by reallocating their assets while exploring new investment opportunities. In the latter case, all stocks come down, and the capital market generally suffers from a change in sentiment and corrects recently exaggerated valuations. In the case of the new megatrend of Artificial Intelligence (AI), the stock market seems to sense a great need for correction. As if by magic, the blockbuster stock Nvidia rose by 250% in just 9 months. However, it has already retraced nearly 20% from its peak. Where do the opportunities lie for investors?

    Read

    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.

    Read